Journal: Journal of medicinal chemistry

Article Title: Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog.

doi: 10.1021/acs.jmedchem.4c00391

Figure Lengend Snippet: Figure 6. AlphaScreen binding assay data for 1 and 15 toward FGFR1c/KLB (A), FGFR3c/KLB (B), and FGFR4/KLB (C). Data are mean ± SEM (n = 3).

Article Snippet: Biotinylated FGF21 was coupled to streptavidin donor beads (PerkinElmer, cat. no. 6760002), and the ectodomain of human FGFR1c, FGFR2c, FGFR3c, or FGFR4 fused to Fc (R&D Systems, cat. no. 685-FR-050, 712-FR-050, 766-FR-050, and 658-FR050) were coupled to Protein A acceptor beads (PerkinElmer, cat. no. 6760137M).

Techniques: Amplified Luminescent Proximity Homogenous Assay, Binding Assay

Journal: Cell Reports Medicine

Article Title: Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma

doi: 10.1016/j.xcrm.2023.101212

Figure Lengend Snippet:

Article Snippet: Recombinant human FGFR4 , Sino Biological , 10538-H08H.

Techniques: Purification, Recombinant, Labeling, Virus, Microarray, Cytokine Assay, Transfection, Chromatin Immunoprecipitation, ChIP-sequencing, Plasmid Preparation, Software, Imaging

Journal: Cancers

Article Title: Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

doi: 10.3390/cancers12113313

Figure Lengend Snippet: Schematic overview of phage display biopanning and preselection of FGFR4 binding single-domain antibodies (sdAb) sequences. Phage display selection was performed on biotinylated and Dynabeads-bound FGFR4 with two different synthetic sdAb phage display libraries. Enriched phage clones were tested for their binding to cell-surface FGFR4 on Rh4-FR4wt cells resulting in 40 unique binders. Eight sdAb were expressed in E. coli and purified. Of these, recombinant A8, B1, B5 and F8 bound to Rh4-FR4wt but not to Rh4-FR4ko cells.

Article Snippet: The specificity of selected phage clones binding to FGFR4 was determined by flow cytometry in 96-well plates (BD Biosciences, Le Pont de Claix, France).

Techniques: Binding Assay, Selection, Clone Assay, Purification, Recombinant

Journal: Cancers

Article Title: Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

doi: 10.3390/cancers12113313

Figure Lengend Snippet: In vitro binding validation of sdAb. ( A ) SdAb were tested for their binding selectivity to cell surface FGFR4 by flow cytometry. Histograms show the single-cell living population of each sdAb binding to Rh4-FR4wt versus Rh4-FR4ko cells. Secondary FITC-labeled anti-6xHis-tag antibody alone (2nd) was used as background control and mCherry (mCh) was used as negative control. Median fluorescence intensities (MFI) were determined with FlowJoTM10 software. Statistics: paired t-test, n = 3 independent experiments, mean + SD, * p ≤ 0.05, ns = not significant. ( B ) Activation assay of FGFR4 in Rh30 cells was performed with recombinant FGF19 and in combination with sdAb. The cells were incubated for 1 h with sdAb at 10 μM (A8, B1, B5, F8, mCh) followed by stimulation of FGFR4 with 50 nM FGF19 for 10 min. Control cells were either not stimulated or stimulated with FGF19 in absence of the sdAb. The cell lysates were analyzed by Western blot with anti-phospho-ERK1/2 antibody. Total Erk1/2 levels are shown as loading control. The complete pictures of the Western blots can be found in .

Article Snippet: The specificity of selected phage clones binding to FGFR4 was determined by flow cytometry in 96-well plates (BD Biosciences, Le Pont de Claix, France).

Techniques: In Vitro, Binding Assay, Flow Cytometry, Labeling, Negative Control, Fluorescence, Software, Activation Assay, Recombinant, Incubation, Western Blot

Journal: Cancers

Article Title: Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

doi: 10.3390/cancers12113313

Figure Lengend Snippet: Affinity determination of sdAb to recombinant protein via surface plasmon resonance spectroscopy. Single-cycle kinetics analysis was performed on immobilized FGFR4 through covalent amine binding on the dextran-based sensor chip. The analytes A8, B1, B5, F8 and mCh were injected in 5 different concentrations followed by a dissociation phase. A final dissociation step was added after the last injection step to determine K off rates for the KD calculations representing binding affinities. The black curves represent the measured data and red curves show the fit analysis (heterogeneous ligand model) performed with the BIAevaluation software.

Article Snippet: The specificity of selected phage clones binding to FGFR4 was determined by flow cytometry in 96-well plates (BD Biosciences, Le Pont de Claix, France).

Techniques: Recombinant, SPR Assay, Spectroscopy, Binding Assay, Injection, Software

Journal: Cancers

Article Title: Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

doi: 10.3390/cancers12113313

Figure Lengend Snippet: Surface plasmon resonance spectroscopic determination of sdAb binding affinities to FGFR4.

Article Snippet: The specificity of selected phage clones binding to FGFR4 was determined by flow cytometry in 96-well plates (BD Biosciences, Le Pont de Claix, France).

Techniques: SPR Assay, Binding Assay

Journal: Cancers

Article Title: Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

doi: 10.3390/cancers12113313

Figure Lengend Snippet: Characterization of FGFR4-targeting and vincristine (VCR)-loaded liposomes.

Article Snippet: The specificity of selected phage clones binding to FGFR4 was determined by flow cytometry in 96-well plates (BD Biosciences, Le Pont de Claix, France).

Techniques:

Journal: Cancers

Article Title: Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

doi: 10.3390/cancers12113313

Figure Lengend Snippet: In vitro binding validation of FGFR4 targeting liposomes. ( A ). Liposomes decorated with FGFR4 targeting sdAb A8, B1, B5 and F8 or mCh (negative control) were tested for their binding selectivity to cell surface FGFR4 by flow cytometry. Adherent cells were incubated for 2 h with 0.5 mM total lipid concentration at 37 °C and 5% CO2. Histograms show the single-cell living population of liposomes binding to Rh4-FR4wt versus Rh4-FR4ko cells. Non-treated cells represent the control populations. Median fluorescence intensities (MFI) are shown. Statistics: paired t -test, n = 3 independent experiments, mean +SD, * p ≤ 0.05, ** p ≤ 0.01. ( B ) Confocal microscopy analysis of Rh4-FR4wt cells incubated for 2 h at 37 °C and 5% CO 2 with sdAb coated fluorescent liposomes. The total lipid concentration was 3 mM. Cells were washed, fixed and mounted with DAPI containing medium. Internalization was visible only in Rh4-FR4wt cells incubated with FGFR4-targeted liposomes.

Article Snippet: The specificity of selected phage clones binding to FGFR4 was determined by flow cytometry in 96-well plates (BD Biosciences, Le Pont de Claix, France).

Techniques: In Vitro, Binding Assay, Negative Control, Flow Cytometry, Incubation, Concentration Assay, Fluorescence, Confocal Microscopy

Journal: Cancers

Article Title: Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

doi: 10.3390/cancers12113313

Figure Lengend Snippet: Cytotoxicity of FGFR4 chimeric antigen receptor (CAR) T cells towards Rhabdomyosarcoma (RMS) cells. ( A ) Schematic representation of the A8FR4 CAR construct. The CAR is composed of the sdAb A8 with CD8α signal peptide sequence and C-terminal myc-tag followed by the hinge and transmembrane (TM) domains of CD8α. Intracellular signaling domains are 4-1BB and CD3ζ and are followed by a streptavidin binding peptide (SBP). ( B ) CD8 + T cell transduction efficiencies of donor B and C were determined by flow cytometry analysis of BFP signal. ( C ) Cytotoxicity was determined by luciferase activity of Rh4 cells co-cultured for 72 h with effector T cells of donors B and C. Relative cell death was highest for Rh4-FR4wt cells incubated with A8FR4 CAR T cells at the indicated effector:target (E:T) cell ratios in both donors. In Rh4-FR4ko cells, non-specific cell killing was observed for the co-cultivation of all CAR T cells and the non-transduced CD8+ T cells. ( D ) Real-time cell death analysis of Rh4 cells co-cultured with effector T cells from donor B using xCELLigence RTCA DP. A8FR4-CAR T cells showed higher killing activity at the indicated E:T cell ratios in Rh4-FR4wt compared to non-specific CD19 CAR T cells or non-transduced CD8 + T cells. In Rh4-FR4ko cells, no specific cytotoxicity was observed. Horizontal lines within the curves indicate the SD of the duplicate wells used during the assay. The asterisks indicate the time of addition of the effector T cells.

Article Snippet: The specificity of selected phage clones binding to FGFR4 was determined by flow cytometry in 96-well plates (BD Biosciences, Le Pont de Claix, France).

Techniques: Construct, Sequencing, Binding Assay, Transduction, Flow Cytometry, Luciferase, Activity Assay, Cell Culture, Incubation